These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945 [TBL] [Abstract][Full Text] [Related]
3. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Golan T; Kanji ZS; Epelbaum R; Devaud N; Dagan E; Holter S; Aderka D; Paluch-Shimon S; Kaufman B; Gershoni-Baruch R; Hedley D; Moore MJ; Friedman E; Gallinger S Br J Cancer; 2014 Sep; 111(6):1132-8. PubMed ID: 25072261 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805 [TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080 [TBL] [Abstract][Full Text] [Related]
6. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593 [TBL] [Abstract][Full Text] [Related]
8. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751 [TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
10. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Kim SH; Hwang HK; Lee WJ; Kang CM Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442 [TBL] [Abstract][Full Text] [Related]
11. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344 [TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Kwa M; Edwards S; Downey A; Reich E; Wallach R; Curtin J; Muggia F Ann Surg Oncol; 2014 May; 21(5):1468-73. PubMed ID: 24081797 [TBL] [Abstract][Full Text] [Related]
13. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591 [TBL] [Abstract][Full Text] [Related]